

MOREPEN LABS GLOBAL LEADER IN DRUG TO FIGHT ASTHMA

New Delhi, 15 May: Morepen Laboratories Ltd. has established leadership position for its anti-asthmatic bulk drug Montelukast in the global market.

As per the latest report published by a global research firm, QYR Research, Morepen is the No1 supplier globally in terms of total quantity sold, followed by Mylan and TAPI (Teva) who appear on the second and third position respectively, Morepen said in a statement here. Montelukast is used in prevention and long-term treatment of asthma.

It is also used in certain patients to relieve allergy symptoms and to prevent asthma attacks caused by exercise. SNS

Company